Oryn Therapeutics is a clinical stage biotechnology company developing Orynotides, a new class of bioinspired macrocyclic peptides as therapeutics for autoimmune and chronic inflammatory diseases, infectious diseases, and oncology.
Orynotides are highly stable cyclic peptides with demonstrated preclinical efficacy in models of each of the listed disease categories.
Oryn’s lead candidate ORTD-1 is a macrocyclic peptide with demonstrated anti-inflammatory properties, initially developed as a subcutaneous injection for the treatment of rheumatoid arthritis (RA).
A Phase 1a study was completed in healthy volunteers demonstrating the safety of subcutaneous ORTD-1, and a Phase 1b study in RA patients is currently now underway.
Oryn has begun a Phase 1b/2 trial evaluating intravenous ORTD-1 for the treatment of SARS-CoV-2–related pneumonia (COVID-19).